Article Text

Download PDFPDF

Secretory symptoms from metastatic adrenal cortical carcinoma responding to octreotide.
  1. H. S. Pandha,
  2. K. Harrington,
  3. S. Saini,
  4. J. Lynn,
  5. M. Peters,
  6. J. Waxman
  1. Department of Clinical Oncology, Hammersmith Hospital, London, UK.


    The prognosis of patients with metastatic adrenal cortical carcinoma is poor, and their disabling symptoms are usually unresponsive to conventional therapy. A patient with Cushing's syndrome secondary to a secretory adrenal cortical carcinoma was treated with octreotide, endocrine therapy and chemotherapy having failed. Treatment led to a dramatic relief of her symptoms with a fall in corticosteroid secretion. Somatostatin analogue therapy for this tumour should be encouraged in view of the lack of alternative palliative treatment.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.